Treatment of Cancer
AssigneeBiPar Sciences, Inc.
InventorsErnest Kun, Jerome Mendeleyev, Carol Basbaurn, Hassan Lemjabbar-Alaoui, Valeria Ossovaskaya
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.
Claims11
A method of treating a cancer comprising administering to a subject in need thereof an effective amount of a composition comprising a compound of formula (Ia)
- wherein R1, R2, R3, R4, and R5 are, independently selected from the group consisting of hydrogen, hydroxy, amino, nitro, iodo, bromo, fluro, chloro, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl, and phenyl, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents are always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts, solvates, isomers, tautomers, metabolites, analogs, or prodrugs thereof,
- wherein said cancer is selected from the group consisting of a ovarian cancer, endometrium cancer, cervical cancer, pancreatic cancer, bladder cancer, eye cancer, central nervous system cancer, kidney cancer, thyroid cancer, and a lung cancer.
A method of treating a cancer comprising administering to a subject in need thereof an effective amount of a composition comprising a compound of formula (Ia)
- wherein R1, R2, R3, R4, and R5 are, independently selected from the group consisting of hydrogen, hydroxy, amino, nitro, iodo, bromo, fluro, chloro, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl, and phenyl, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents are always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts, solvates, isomers, tautomers, metabolites, analogs, or prodrugs thereof,
- wherein said cancer is selected from the group consisting of a mammary gland ductal carcinoma, breast infiltrating carcinoma of lobular type, breast intraductal carcinoma, breast mucinous carcinoma, promyleocytic leukemia in the peripheral blood, an ovarian adenocarcinoma, an ovarian adenocarcinoma that has migrated into the abdominal cavity, a prostate adenocarinoma, a transitional cell carcinoma of the bladder, an epitheliod carcinoma in a pancreatic duct, an adenocarcinoma in a pancreatic duct, an adenocarcinoma in the cervical epithelium, and a lung cancer.
A method of treating a cancer comprising administering to a subject in need thereof an effective amount of a composition comprising a compound of formula (Ia)
- wherein R1, R2, R3, R4, and R5 are, independently selected from the group consisting of hydrogen, hydroxy, amino, nitro, iodo, bromo, fluro, chloro, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl, and phenyl, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents are always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts, solvates, isomers, tautomers, metabolites, analogs, or prodrugs thereof,
- wherein said cancer is selected from the group consisting of a breast infiltrating carcinoma of lobular type, breast intraductal carcinoma and breast mucinous carcinoma.
A method of treating a cancer comprising administering to a subject in need thereof an effective amount of a composition comprising a compound of formula (Ia)
- wherein R1, R2, R3, R4, and R5 are, independently selected from the group consisting of hydrogen, hydroxy, amino, nitro, iodo, bromo, fluro, chloro, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl, and phenyl, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents are always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts, solvates, isomers, tautomers, metabolites, analogs, or prodrugs thereof,
- wherein said cancer is selected from the group consisting of a colon cancer, prostate cancer, liver cancer, leukemia, glioma, and melanoma.
Dependencies are inferred from the claim text.